A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Clinical trial NCT05933577 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05933577
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-19
- Primary completion
- 2029-10-26
- Enrollment
- 1089
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.